Jaguar Health Declares Special Series R Preferred Dividend — 5-for-1 Conversion Could Add 11.6M Shares
JAGX sits 78% above its 52-week low of $2.35.
Summary
Jaguar Health declared a special Series R Preferred Stock dividend that converts 5-for-1 into common stock on November 2, 2026, potentially adding up to 11.6 million shares. The company also extended royalty payment and note maturity deadlines to January 1, 2027.
Key Events · Financing and Capital Events · JAGX
-
Special Series R Preferred Dividend Declared
Board declared a one-time dividend of one share of Series R Convertible Preferred Stock for each common share (and certain warrant shares) held as of record date October 13, 2026, payable October 15, 2026.
-
5-for-1 Conversion Creates Massive Dilution
Each Series R preferred share automatically converts into 5 common shares on November 2, 2026. Based on 2,138,712 common shares outstanding as of October 1, 2026 plus 142,535 eligible warrant shares, up to 11,406,235 new common shares would be issued — approximately 83.3% of the post-conversion share count.
-
Debt and Royalty Payments Pushed to January 2027
Amendments with Uptown Capital and Streeterville Capital extended the start of $750,000 minimum monthly royalty payments from October 1, 2026 to January 1, 2027. The $6,220,812.50 secured promissory note maturity was also extended to January 1, 2027.
-
C/M Capital Consent and Waiver
C/M Capital consented to the Series R dividend and waived participation rights in exchange for Jaguar's agreement to repurchase all outstanding Series P Preferred Stock for cash upon any Fundamental Transaction, subject to legal availability of funds.
Analysis · JAGX · Life Sciences
A special one-time dividend of Series R Convertible Preferred Stock has been declared for all common shareholders and certain warrant holders. Each preferred share automatically converts into five common shares on November 2, 2026, potentially issuing up to 11.6 million new common shares — roughly 83% of the current 2.14 million shares outstanding. The company frames this as dilution protection for existing holders while it evaluates strategic alternatives, but the mechanics create a massive overhang: anyone buying common stock after the record date without receiving the preferred dividend faces severe dilution. Simultaneously, Jaguar pushed back $750,000 monthly royalty payments and a $6.2 million note maturity from October 1, 2026 to January 1, 2027, buying three months of runway against a going-concern backdrop with only $3.8 million in cash as of the last 10-Q.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JAGX was trading at $4.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.1M. The 52-week trading range was $2.35 to $1,267.88. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.